New boss but Bayer's battles go on

8 November 2023

German life sciences major Bayer (BAYN: DE) has confirmed its group outlook for 2023 after posting third-quarter figures that were down against the previous year.

Sales slipped by a worrying 8% to 10.34 billion euros ($11.03 billion) while third-quarter earnings before interest, tax, depreciation and amortisation (EBITDA) and adjusted for one-off effects fell 31% to 1.69 billion euros, hit by lower earnings at its crop science division. This compared with analysts' average forecast of 1.73 billion euros. Pharmaceuticals Division sales were level, at 4.54 billion euros.

"We’re not happy with this year’s performance. Nearly 50 billion euros in revenue but zero cash flow is simply not acceptable"The group made a quarterly net loss of 4.57 billion euros against a profit of 546 million euros a year earlier. Impairment charges at the crop science unit due to higher interest rates contributed to this.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK